Inhibition of monocyte chemotaxis by VB-201, a small molecule lecinoxoid, hinders atherosclerosis development in ApoE-/- mice

Atherosclerosis

Volumn 229, Issue 2, 2013, Pages 430-439

  Feige, Erez ^a   Yacov, Niva ^a   Salem, Yaniv ^a   Levi, Itzhak ^a   Mendel, Itzhak ^a   Propheta Meiran, Oshrat ^a   Shoham, Anat ^a   Hait Darshan, Ravit ^a   Polonsky, Omri ^a   George, Jacob ^a   Harats, Dror ^a   Breitbart, Eyal ^a  

^a VBL Therapeutics   (Israel)

Author keywords

Chemotaxis; Inflammation; Lecinoxoids; Oxidized phospholipids

Indexed keywords

PHOSPHOLIPID DERIVATIVE; UNCLASSIFIED DRUG; VB 201;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATHEROSCLEROSIS; CHEMOTAXIS; CONTROLLED STUDY; DRUG EFFECT; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LEUKOCYTE ADHERENCE; MALE; MONOCYTE; MOUSE; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL;

1-PALMITOYL-2-ARACHIDONOYL-SN-GLYCERO-3-PHOSPHOCHOLINE; 1-PALMITOYL-2-GLUTARYL PHOSPHATIDYLCHOLINE; CHEMOTAXIS; DC; DENDRITIC CELL; FACS; FLUORESCENCE-ACTIVATED CELL SORTING; G-PROTEIN COUPLED RECEPTOR; GPCR; INFLAMMATION; LDL; LECINOXOIDS; LOW DENSITY LIPOPROTEIN; MCP-1; MONOCYTE CHEMOTACTIC PROTEIN-1; OXIDIZED PAPC; OXIDIZED PHOSPHOLIPID; OXIDIZED PHOSPHOLIPIDS; OXPAPC; OXPL; PAPC; PGPC; REACTIVE OXYGEN SPECIES; ROS;

ANIMALS; APOLIPOPROTEINS E; ATHEROSCLEROSIS; CELLS, CULTURED; CHEMOTAXIS; CHOLESTEROL; DISEASE MODELS, ANIMAL; FEMALE; FLOW CYTOMETRY; GLYCERYLPHOSPHORYLCHOLINE; HUMANS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MONOCYTES; PERITONITIS; RECEPTORS, CHEMOKINE; SIGNAL TRANSDUCTION; TRIGLYCERIDES; VASCULITIS;

EID: 84880606569     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2013.06.005     Document Type: Article

References (32)

1. Kamei M., Carman C.V. New observations on the trafficking and diapedesis of monocytes. Curr Opin Hematol 2010, 17:43-52.
2. Geissmann F., Manz M.G., Jung S., Sieweke M.H., Merad M., Ley K. Development of monocytes, macrophages, and dendritic cells. Science (New York, N.Y.) 2010, 327:656-661.
3. Zhao Q. Dual targeting of CCR2 and CCR5: therapeutic potential for immunologic and cardiovascular diseases. JLeukoc Biol 2010, 88:41-55.
4. Moore K.J., Tabas I. Macrophages in the pathogenesis of atherosclerosis. Cell 2011, 145:341-355.
5. Mildner A., Mack M., Schmidt H., Bruck W., Djukic M., Zabel M.D., et al. CCR2+Ly-6Chi monocytes are crucial for the effector phase of autoimmunity in the central nervous system. Brain 2009, 132:2487-2500.
6. Imhof B.A., Aurrand-Lions M. Adhesion mechanisms regulating the migration of monocytes. Nat Rev Immunol 2004, 4:432-444.
7. Mackay C.R. Moving targets: cell migration inhibitors as new anti-inflammatory therapies. Nat Immunol 2008, 9:988-998.
8. Bochkov V.N., Oskolkova O.V., Birukov K.G., Levonen A.L., Binder C.J., Stockl J. Generation and biological activities of oxidized phospholipids. Antioxid Redox Signal 2010, 12:1009-1059.
9. Leitinger N. The role of phospholipid oxidation products in inflammatory and autoimmune diseases: evidence from animal models and in humans. Subcell Biochem 2008, 49:325-350.
10. Berliner J.A., Gharavi N.M. Endothelial cell regulation by phospholipid oxidation products. Free Radic Biol Med 2008, 45:119-123.
11. Bochkov V.N. Inflammatory profile of oxidized phospholipids. Thromb Haemost 2007, 97:348-354.
12. Navab M., Hama S.Y., Reddy S.Y., Ng C.J., Van Lenten B.J., Laks H., et al. Oxidized lipids as mediators of coronary heart disease. Curr Opin Lipidol 2002, 13:363-372.
13. Feige E., Mendel I., George J., Yacov N., Harats D. Modified phospholipids as anti-inflammatory compounds. Curr Opin Lipidol 2010, 21:525-529.
14. Bochkov V.N., Kadl A., Huber J., Gruber F., Binder B.R., Leitinger N. Protective role of phospholipid oxidation products in endotoxin-induced tissue damage. Nature 2002, 419:77-81.
15. Nonas S., Birukova A.A., Fu P., Xing J., Chatchavalvanich S., Bochkov V.N., et al. Oxidized phospholipids reduce ventilator-induced vascular leak and inflammation invivo. Crit Care 2008, 12:R27.
16. Bluml S., Zupkovitz G., Kirchberger S., Seyerl M., Bochkov V.N., Stuhlmeier K., et al. Epigenetic regulation of dendritic cell differentiation and function by oxidized phospholipids. Blood 2009, 114:5481-5489.
17. Siess W. Athero- and thrombogenic actions of lysophosphatidic acid and sphingosine-1-phosphate. Biochim Biophys Acta 2002, 1582:204-215.
18. Smith J.D., Trogan E., Ginsberg M., Grigaux C., Tian J., Miyata M. Decreased atherosclerosis in mice deficient in both macrophage colony-stimulating factor (op) and apolipoprotein E. Proc Natl Acad Sci U S A 1995, 92:8264-8268.
19. Qiao J.H., Tripathi J., Mishra N.K., Cai Y., Tripathi S., Wang X.P., et al. Role of macrophage colony-stimulating factor in atherosclerosis: studies of osteopetrotic mice. Am J Pathol 1997, 150:1687-1699.
20. Ley K., Miller Y.I., Hedrick C.C. Monocyte and macrophage dynamics during atherogenesis. Arterioscler Thromb Vasc Biol 2011, 31:1506-1516.
21. Mendel I., Shoham A., Propheta-Meiran O., Ishai E., Halperin G., Feige E., et al. Alecinoxoid, an oxidized phospholipid small molecule, constrains CNS autoimmune disease. JNeuroimmunol 2010, 226:126-135.
22. Cole A.L., Subbanagounder G., Mukhopadhyay S., Berliner J.A., Vora D.K. Oxidized phospholipid-induced endothelial cell/monocyte interaction is mediated by a cAMP-dependent R-Ras/PI3-kinase pathway. Arterioscler Thromb Vasc Biol 2003, 23:1384-1390.
23. Leitinger N. Oxidized phospholipids as modulators of inflammation in atherosclerosis. Curr Opin Lipidol 2003, 14:421-430.
24. Li Y.M., Baviello G., Vlassara H., Mitsuhashi T. Glycation products in aged thioglycollate medium enhance the elicitation of peritoneal macrophages. JImmunol Methods 1997, 201:183-188.
25. Murphy A.J., Akhtari M., Tolani S., Pagler T., Bijl N., Kuo C.L., et al. ApoE regulates hematopoietic stem cell proliferation, monocytosis, and monocyte accumulation in atherosclerotic lesions in mice. JClin Invest 2011, 121:4138-4149.
26. Horuk R. Chemokine receptor antagonists: overcoming developmental hurdles. Nat Rev Drug Discov 2009, 8:23-33.
27. Pease J.E., Horuk R. Chemokine receptor antagonists: part 2. Expert Opin Ther Pat 2009, 19:199-221.
28. Selvaraj S.K., Giri R.K., Perelman N., Johnson C., Malik P., Kalra V.K. Mechanism of monocyte activation and expression of proinflammatory cytochemokines by placenta growth factor. Blood 2003, 102:1515-1524.
29. Wain J.H., Kirby J.A., Ali S. Leucocyte chemotaxis: examination of mitogen-activated protein kinase and phosphoinositide 3-kinase activation by monocyte chemoattractant proteins-1, -2, -3 and -4. Clin Exp Immunol 2002, 127:436-444.
30. Egger M., Beer A.G., Theurl M., Schgoer W., Hotter B., Tatarczyk T., et al. Monocyte migration: a novel effect and signaling pathways of catestatin. Eur J Pharmacol 2008, 598:104-111.
31. Di Lorenzo A., Fernandez-Hernando C., Cirino G., Sessa W.C. Akt1 is critical for acute inflammation and histamine-mediated vascular leakage. Proc Natl Acad Sci U S A 2009, 106:14552-14557.
32. Hirsch E., Katanaev V.L., Garlanda C., Azzolino O., Pirola L., Silengo L., et al. Central role for G protein-coupled phosphoinositide 3-kinase gamma in inflammation. Science 2000, 287:1049-1053.